Clinical Trial Update: Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK) [Phase 2]

View source ↗

Summary

Clinical trial update for MASTERPROTOCOL ALK (NCT05200481) evaluating brigatinib with or without chemotherapy in advanced ALK-positive non-small cell lung cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Brigatinib (brigatinib)

Snippet

Sponsor: Intergroupe Francophone de Cancerologie Thoracique | Conditions: Non Small Cell Lung Cancer, ALK Gene Mutation | Phase 2 | Status: ACTIVE_NOT_RECRUITING